Evidence map›Paper›PMID 31558185›Full record

ArticleOncology research2020

PRKAA1 Promotes Proliferation and Inhibits Apoptosis of Gastric Cancer Cells Through Activating JNK1 and Akt Pathways.

Yangmei Zhang, Xichang Zhou, Long Cheng, Xiang Wang, Qinglin Zhang, Youwei Zhang, Sanyuan Sun

Open access · hybridAbstract read
In one paragraph

Article in Oncology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Anticancer activities of natural abietic acid.Frontiers in pharmacology · 2024
    Review
  10. Article
  11. Transcriptomics analyses reveal the effects of Pentagamaboronon-0-ol on PI3K/Akt and cell cycle of HER2+ breast cancer cells.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yangmei ZhangDepartment of Oncology, Xuzhou Central Hospital, Xuzhou Medical UniversityXuzhouP.R. China.
Xichang ZhouDepartment of Intervention, Xuzhou Central Hospital, Xuzhou Medical UniversityXuzhouP.R. China.
Long ChengDepartment of Intervention, Xuzhou Central Hospital, Xuzhou Medical UniversityXuzhouP.R. China.
Xiang WangDepartment of Oncology, Xuzhou Central Hospital, Xuzhou Medical UniversityXuzhouP.R. China.
Qinglin ZhangDepartment of Central Laboratory, Xuzhou Central Hospital, Xuzhou Medical UniversityXuzhouP.R. China.
Youwei ZhangDepartment of Oncology, Xuzhou Central Hospital, Xuzhou Medical UniversityXuzhouP.R. China.
Sanyuan SunDepartment of Oncology, Xuzhou Central Hospital, Xuzhou Medical UniversityXuzhouP.R. China.
Xuzhou Medical College · CNXuzhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PRKAA1 (protein kinase AMP-activated catalytic subunit α 1) is a catalytic subunit of AMP-activated protein kinase (AMPK), which plays a key role in regulating cellular energy metabolism through phosphorylation, and genetic variations in the PRKAA1 have been found to be associated with gastric cancer risk. However, the effect and underlying molecular mechanism of PRKAA1 on gastric cancer tumorigenesis, especially the proliferation and apoptosis, are not fully understood. Our data showed that PRKAA1 is highly expressed in BGC-823 and MKN45 cells and is expressed low in SGC-7901 and MGC-803 cells in comparison with the other gastric cancer cells. PRKAA1 downregulation by shRNA or treatment of AMPK inhibitor compound C significantly inhibited proliferation as well as promoted cell cycle arrest and apoptosis of BGC-823 and MKN45 cells. Moreover, the expression of PCNA and Bcl-2 and the activity of JNK1 and Akt signaling were also reduced in BGC-823 and MKN45 cells after PRKAA1 downregulation. In vivo experiments demonstrated that tumor growth in nude mice was significantly inhibited after PRKAA1 silencing. Importantly, inactivation of JNK1 or Akt signaling pathway significantly inhibited PRKAA1 overexpression-induced increased cell proliferation and decreased cell apoptosis in MGC-803 cells. In conclusion, our findings suggest that PRKAA1 increases proliferation and restrains apoptosis of gastric cancer cells through activating JNK1 and Akt pathways.

Indexed as

ApoptosisSignal TransductionAMP-Activated Protein KinasesAnimalsCell Cycle CheckpointsCell Line, TumorCell MovementCell ProliferationDisease Models, AnimalGene ExpressionHumansMaleMiceMice, NudeMitogen-Activated Protein Kinase 8Proliferating Cell Nuclear AntigenAMP-Activated Protein KinasesBCL2 protein, humanMitogen-Activated Protein Kinase 8PCNA protein, humanPRKAA1 protein, humanProliferating Cell Nuclear AntigenProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-bcl-2

Identifiers

PMID31558185
PMCPMC7851536
OpenAlexW2975647676

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.